Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 10 institutions in 1 country.
Jorge R KizerCardiology Section, San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.
Sheena PatelResearch Institute, California Pacific Medical Center, San Francisco, California, USA.
Peter GanzDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-0437-8882
Anne B NewmanDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-0106-1150
Shalender BhasinResearch Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-3982-6200
Se-Jin LeeThe Jackson Laboratory and University of Connecticut School of Medicine, Farmington, Connecticut, USA.
Peggy M CawthonDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Nathan K LeBrasseurRobert and Arlene Kogod Center on Aging, and Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA.
Sanjiv J ShahDivision of Cardiology, Department of Medicine, Northwestern University School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-5655-8201
Bruce M PsatyCardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Systems and Population Health, University of Washington, Seattle, Washington, USA.
Russell P TracyDepartment of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
Steven R CummingsDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · USBrigham and Women's Hospital · USCalifornia Pacific Medical Center · USMayo Clinic in Florida · USNorthwestern University · USSan Francisco General Hospital · USUniversity of Connecticut · USUniversity of Pittsburgh · USUniversity of Vermont · USUniversity of Washington · US
Funding
Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
CHS research resources for the cardiovascular health of older adultsU01HL130114 · NHLBI · UNIVERSITY OF WASHINGTON · PI BURKE, GREGORY L, KRONMAL, RICHARD A · 2016 to 2019
$6.6M
CHS Events Follow-up StudyU01HL080295 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2005 to 2008
$4.6M
Peripheral Nerve Function Decline in an Aged CohortR01AG028050 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STROTMEYER, ELSA S. · 2007 to 2015
$3.5M
Non-esterified fatty acids and dementia: risk, structure, and biomarkersR01AG053325 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DJOUSSE, LUC, MUKAMAL, KENNETH JAY · 2016 to 2019
$3.5M
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins - SUPPLEMENTR01AG052964 · NIA · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI CUMMINGS, STEVEN RON, GANZ, PETER · 2016 to 2020
$3.2M
End of Life in the Very OldR01NR012459 · NINR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ALBERT, STEVEN M, LUNNEY, JUNE R · 2011 to 2015
$2.7M
Role of EIIIA fibronectin in pulmonary fibrosisR01HL085083 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WHITE, ERIC S · 2007 to 2011
$1.9M
DYNAMICS OF HEALTH .AGING . AND BODY COMPOSITION /Pittsburgh/-260962101N01AG062101 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1996 to 2004
$996k
DYNAMICS OF HEALTH . AGING . AND BODY COMPOSITION /Memphis/-26062103N01AG062103 · NIA · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 1996 to 2004
$793k
CHS-Transition PhaseN01HC55222 · NHLBI · PI , · 2007 to 2007
$575k
HEALTH ABC--COORDINATING UNIT /California/-260062106N01AG062106 · NIA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 1996 to 2004
backgroundHeterochronic parabiosis has identified growth differentiation factor (GDF)-11 as a potential means of cardiac rejuvenation, but findings have been inconsistent. A major barrier has been lack of assay specificity for GDF-11 and its homolog GDF-8.
methodsWe tested the hypothesis that GDF-11 and GDF-8, and their major antagonists follistatin and follistatin-like (FSTL)-3, are associated with incident heart failure (HF) and its subtypes in elders. Based on validation experiments, we used liquid chromatography-tandem mass spectrometry to measure total serum GDF-11 and GDF-8, along with follistatin and FSTL-3 by immunoassay, in 2 longitudinal cohorts of older adults.
resultsIn 2 599 participants (age 75.2 ± 4.3) followed for 10.8 ± 5.6 years, 721 HF events occurred. After adjustment, neither GDF-11 (HR per doubling: 0.93 [0.67, 1.30]) nor GDF-8 (HR: 1.02 per doubling [0.83, 1.27]) was associated with incident HF or its subtypes. Positive associations with HF were detected for follistatin (HR: 1.15 [1.00, 1.32]) and FLST-3 (HR: 1.38 [1.03, 1.85]), and with HF with preserved ejection fraction for FSTL-3 (HR: 1.77 [1.03, 3.02]). (All HRs per doubling of biomarker.) FSTL-3 associations with HF appeared stronger at higher follistatin levels and vice versa, and also for men, Blacks, and lower kidney function.
conclusionsAmong older adults, serum follistatin and FSTL-3, but not GDF-11 or GDF-8, were associated with incident HF. These findings do not support the concept that low serum levels of total GDF-11 or GDF-8 contribute to HF late in life, but do implicate transforming growth factor-β superfamily pathways as potential therapeutic targets.
Indexed as
Bone Morphogenetic ProteinsGrowth Differentiation FactorsHeart FailureMyostatinAgedBiomarkersFollistatinGrowth Differentiation Factor 15HumansMaleBiomarkersBone Morphogenetic ProteinsFollistatinGDF11 protein, humanGrowth Differentiation Factor 15Growth Differentiation FactorsMSTN protein, humanMyostatinFollistatinFollistatin-like 3Growth and differentiation factor 11Growth and differentiation factor 8Heart failure
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Circulating Growth Differentiation Factors 11 and 8, Their Antagonists Follistatin and Follistatin-Like-3, and Risk of Heart Failure in Elders. · full record | OpenQuestion